Taxotere (docetaxel) is a popular chemotherapy drug manufactured and marketed by Sanofi-Aventis. The drug is also the most prescribed drug in its class. In 2009, Taxotere made over $3 billion for Sanofi before the company lost patent protection.
The treatment plan for Taxotere is once every three weeks, unlike paclitaxel — a drug in the same class — which is weekly. So, patients make a trip to receive treatment less often, an idea that is attractive to many women.
Some doctors prescribe Taxotere to their patients for reasons of convenience, though studies show paclitaxel is just as effective. We can say that Taxotere hair loss lawsuit may be an option for patients who suffered from permanent hair loss after taking the drug as a part of their chemotherapy treatment for certain forms of cancer.
But, studies also linked the drug to a disfiguring side effect: permanent hair loss, also called alopecia. In some cases, about 9 percent of breast cancer patients suffered alopecia that lasted for a decade or more, severely decreasing their quality of life, negatively affecting body image and causing depression and distress.
Now, breast cancer survivors and their families are filing lawsuits against Sanofi, claiming the company failed to warn them of the risk and hid research linking the chemo drug to the toxic side effects.
Hair loss during chemotherapy is expected. It is a very common side effect of fighting cancer. But, women who underwent treatment with Taxotere did not prepare themselves for permanent loss of their hair. What angers many of these women and their families is that they were never properly warned of the risk so they could make an informed choice. Click here for further information about hair damage lawsuits or you can visit its official website.
The permanent loss of hair is more than cosmetic. For breast cancer survivors, it is a constant reminder of their struggle. For them, life will never be the same.
Lawsuits filed against Sanofi-Avents claim several legal actions against the drug maker, including:
- Selling the drug without properly testing it.
- Failing to determine whether the drug was safe.
- Selling the drug without disclosing the dangers or risks.
- Failing to properly warn patients and health care providers.
- Misleading the public in advertising and marketing.
Studies the company should have been aware of include:
In the late 1990s, Sanofi sponsored a study called GEICAM 9805. By 2005, the company knew that the results of this trial revealed 9.2 percent of women who used the chemo drug suffered permanent alopecia.